权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

IPSC phenotype, mitochondrial haplotype and psychosis in 22q11 deletion syndrome

22q11 缺失综合征中的 IPSC 表型、线粒体单倍型和精神病

基本信息

批准号：
9355237
负责人：
Stewart A Anderson
金额：
$ 50.74万
依托单位：
CHILDREN'S HOSP OF PHILADELPHIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-20 至 2019-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9355237
关键词：
22q11 22q11 Deletion Syndrome 22q11.2 Age Antioxidants Bioenergetics Bioinformatics Birth Child Chronic Complex Core Protein Data Development Disease Electron Transport Enrollment Functional disorder Future Genes Genetic Genus Hippocampus Goals Haplogroup Haplotypes International Investigation Lead Mediating Messenger RNA Metabolic Mitochondria Mitochondrial DNA Mitochondrial Proteins Morphology Mutation Neuronal Dysfunction Neurons Nuclear Oxidative Phosphorylation Oxygen saturation measurement PTGS1 gene Patients Phenotype Prevention Prosencephalon Protein Biosynthesis Proteins Psychotic Disorders Reactive Oxygen Species Recording of previous events Ribosomes Risk Schizophrenia Secondary to Stem cells Symptoms System Technology Testing Therapeutic Agents Translating Translations Variant base brain behavior cohort computerized data processing conotruncal anomaly face syndrome cytochrome c oxidase experimental study gene function genetic analysis genetic risk factor genome editing high risk improved induced pluripotent stem cell mitochondrial dysfunction multidisciplinary neuropsychiatry novel novel strategies oxidative damage prospective protein expression protein function screening synaptogenesis whole genome

项目摘要

Metabolic compromise, including mitochondrial dysfunction, may contribute to the development of symptoms in schizophrenia. However, approaches to explore the relationship between mitochondrial dysfunction, neural dysfunction, and schizophrenia risk are needed. The most common genetic risk factor for schizophrenia is the 22q11.2 deletion syndrome (22q11DS), associated with a 25% risk of developing this disorder. Interestingly, in 22q11DS six of the roughly 40 deleted genes encode for mitochondrial-localizing proteins. We have assembled a multidisciplinary team to combine the use of stem cell derived neurons from 22q11DS patients with or without schizophrenia, and controls, with genetic analyses of 22q11DS patients with and without schizophrenia. We will test the hypothesis that a “second hit” within mitochondrial-related genes in the 22q11DS context increases metabolic dysfunction in neurons and is associated with an increased risk for schizophrenia in patients. Aim 1. Investigation of mitochondrial function in 22q11DS derived forebrain neurons. Existing IPSC lines from 3 groups will be compared: 1) 22q11DS with schizophrenia, 2) 22qDS without schizophrenia or history of psychosis (and over the age of 25), and healthy controls. Forebrain-like neurons from these lines will be compared for evidence of mitochondrial dysfunction that is most pronounced in the 22q11DS+SZ group. Consistent with the fact that one of the 22q11-deleted genes is MRPL40, a subunit of the mitochondrial ribosome, our preliminary evidence suggests that IPSC-derived neurons from the 22q11DS+SZ group have reduced translation of COX1, a key mitochondrial DNA-encoded protein. They also have significantly reduced cytochrome C oxidase activity, and strong evidence of oxidative damage. Aim 2. Are genetic “second hits” to mitochondrial function associated with psychosis in 22q11DS? We will use whole genome sequence data from about 600 22q11DS patients, evenly split between those with and without chronic psychosis, from the International 22q11.2DS Brain and Behavior Consortium (22QIBBC). Bioinformatic processing will determine whether the risk of developing SZ in 22q11DS is potentially influenced by the mitochondrial haplogroup, or is associated with an increased presence of mutations in mtDNA, or is associated with an increased presence of mutations in nuclear-encoded genes that generate mitochondrial- functioning proteins. Future studies would employ mitochondrial cybrids (`swapping”) technology, genome editing, “putback” experiments, and other approaches to test the functional relevance of findings from Aim 2 on mitochondrial function in 22q11DS-derived IPSCs, and could be extended to IPSCs from other high-risk SZ groups. These results could also be used to examine the prospective risk of 22q11DS children to develop chronic psychosis, using the large cohort of subjects currently being enrolled and studied by the 22QIBBC. Significance The results of this study could lead to improved prediction, treatment, and prevention of psychosis in 22q11DS, and could generalize to the treatment or prevention of psychosis beyond 22q11DS.

代谢损害，包括线粒体功能障碍，可能有助于症状的发展